ERBB2 and non-small cell lung carcinoma: In a phase II basket trial, ado‐trastuzumab emtansine (TDM1), a HER2‐targeted antibody–drug conjugate (ADC) has shown an ORR of 44% [95% CI: 22%–69%] in HER2‐positive NSCLC patients.15